Abstract 66P
Background
Extremity STS poses a considerable challenge due to its propensity for local recurrence despite advancements in treatment modalities. The nomogram construction involved comprehensive analysis of clinicopathological variables, treatment regimens, and patient outcomes, aiming to offer a reliable and personalized predictive tool. Through rigorous statistical modeling, this nomogram integrates pertinent prognostic factors, enabling clinicians to estimate an individual's risk of local recurrence with enhanced precision. Implementation of this nomogram holds significant promise in guiding clinical decision-making, facilitating tailored surveillance strategies, and ultimately improving patient care by enabling proactive interventions to mitigate the risk of local recurrence in extremity soft tissue sarcoma.
Methods
A retrospective review of our prospective sarcoma database identified 1000 patients with primary, nonmetastatic soft tissue sarcomas (STS) who underwent surgery with radiotherapy and/or chemotherapy exclusively between June 1993 and December 2021. Clinicopathologic factors such as age, sex, grade, depth, size, site, margin status, and adjuvant treatments were assessed for their prognostic significance in relation to local recurrence rates. Variables exhibiting significance in univariate analysis at the 0.05 level were incorporated into a multivariate competing risk regression model. Subsequently, a nomogram predicting the 5-year LR risk was developed based on the outcomes of the multivariate analysis.
Results
A total of 1000 patients were included. In a median follow-up of 37 months, 30.5% (305) of patients developed recurrence. Of these, there were 11.5% LR and 19% SR. The nomogram encompassed factors like age (≤50 vs >50), site (extremity vs non extremity), margin status (negative vs positive), depth (superficial vs deep), and adjuvant radiation (yes vs no).
Conclusions
The established nomogram tailored for extremity STS, incorporating age, site, margin status, tumour depth, and adjuvant radiation, effectively forecasts 5-year risk of local recurrence following completion of treatment of soft tissue sarcoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AIIMS, New Delhi, India.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.